Antibiotic analog of CLOXACILLIN.

Acute bronchopulmonary infection due to Streptococcus milleri in a child with cystic fibrosis. (1/84)

An 8 year old girl with cystic fibrosis had severe respiratory disease associated with chronic Pseudomonas aeruginosa bronchopulmonary infection. Despite regular courses of intravenous antipseudomonal antibiotics, she continued to deteriorate over 18 months with persistent productive cough, worsening respiratory function, and increasing oxygen dependence. During her 11th admission Streptococcus milleri was isolated from sputum cultures in addition to P aeruginosa. She failed to respond to antipseudomonal antibiotics but improved dramatically with the addition of intravenous benzylpenicillin. Although S milleri is considered a normal mouth commensal and its isolation from sputum of cystic fibrosis patients is of uncertain significance, it was associated with clinically significant infection in this child. S milleri was eradicated with antibiotic treatment and clinical improvement has been maintained.  (+info)

The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. (2/84)

Since the efficacy of beta-lactams against pathogens such as methicillin-susceptible Staphylococcus aureus (MSSA) is related to the time for which serum drug concentrations exceed the MIC for the pathogen, administration of anti-staphylococcal beta-lactams by continuous infusion may provide a more suitable means of drug delivery than intermittent dosing. To assess the clinical efficacy of continuous-infusion therapy, we reviewed the outcomes for 20 consecutive patients with proven serious MSSA sepsis (three with endocarditis, ten osteomyelitis, one endocarditis plus osteomyelitis and six deep abscess) treated with continuous-infusion flucloxacillin (8-12 g/day). Patients initially receiving routine intermittent-dose flucloxacillin therapy were changed to continuous-infusion flucloxacillin (mean duration 29 days; range 4-60 days) for completion of their treatment course. In the majority of cases this was given at home. Serum flucloxacillin concentrations during continuous-infusion flucloxacillin 12 g/day were 11.5->40 mg/L (ten patients) and those during continuous-infusion flucloxacillin 8 g/day were 8->40 mg/L (five patients), these concentrations being well above the expected MIC of flucloxacillin for MSSA. Continuous-infusion flucloxacillin was well tolerated by most patients, and 14/17 patients (82%) who completed their course of continuous-infusion flucloxacillin were judged clinically and microbiologically cured at long-term follow-up (mean 67 weeks; range 4-152 weeks). These preliminary data suggest that, following initial intermittent-dose flucloxacillin therapy, continuous-infusion flucloxacillin is an effective treatment option for serious MSSA sepsis, and forms a feasible and possibly preferable alternative to glycopeptides when considering home-based parenteral therapy for these infections. Further studies are needed to identify whether continuous-infusion flucloxacillin can entirely replace intermittent-dose therapy for such infections.  (+info)

Further evolution of a strain of Staphylococcus aureus in vivo: evidence for significant inactivation of flucloxacillin by penicillinase. (3/84)

A strain of Staphylococcus aureus (no. FAR4) has been isolated at intervals, for 32 months, from the sputum of a patient with cystic fibrosis of the lung. Changes in the properties of isolates of this strain over the first 18 months have been reported previously (Lacey et al., 1973 and 1974). During the last 14 months (May 1973 to July 1974), further evolution has occurred to produce a total of 31 distinct phenotypes. Recent changes are as follows. 1. The ability of isolates to produce penicillinase in vitro was closely correlated with flucloxacillin therapy. Inactivation of flucloxacillin by penicillinase was demonstrated by diffusion testing (but not MIC determination) in vitro and may have occurred to a significant extent in vivo. 2. Lincomycin-resistant mutants slowly disappeared from the sputum after the termination of clindamycin therapy. 3. All of the recent isolates were resistant to erythromycin, possibly because of the linkage of the genes coding for erythromycin resistance with those coding for the production of delta-haemolysin; delta-haemolysin may be an important "virulence factor".  (+info)

Septic arthritis due to Streptococcus pneumoniae in Nottingham, United Kingdom, 1985-1998. (4/84)

Pneumonia and meningitis are the 2 most frequent manifestations of Streptococcus neumoniae infection. Pneumococcal septic arthritis is considered to be relatively uncommon. Between 1985 and 1998, 32 (8. 2%) of 389 cases of septic arthritis seen in the 2 hospitals in Nottingham, United Kingdom, were due to S. pneumoniae. Six of 7 children with pneumococcal septic arthritis were aged <2 years. Of the 25 adults, 20 (80%) were aged >60 years, 11 (44%) had concomitant pneumococcal infection elsewhere, and 23 (92%) had articular or nonarticular diseases and/or other risk factors. In the elderly, a lack of febrile response was striking. S. pneumoniae was isolated from blood and joint cultures in >70% of cases, and gram-positive diplococci were seen in the joint fluids of 90% of patients. The mean duration of antimicrobial therapy for adults was twice as long as that for children. Eight (32%) of the adults died.  (+info)

Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. (5/84)

A new cream formulation of mupirocin developed to improve patient compliance was compared with systemic and topical antibiotics commonly used to treat primary and secondary skin infections. A mouse surgical wound model infected with Staphylococcus aureus or Streptococcus pyogenes was used. Topical treatment was applied at 4 and 10 h postinfection or oral treatment at a clinically relevant dose was administered 4, 8, and 12 h postinfection; treatments were continued three times daily for a further 3 days. Mupirocin cream was significantly more effective than (P < 0.01; two of eight studies) or not significantly different from (six of eight studies) mupirocin ointment in reducing bacterial numbers. Mupirocin cream was similar in efficacy to oral flucloxacillin but significantly more effective (P < 0.001) than oral erythromycin. It was also similar in efficacy to cephalexin against S. pyogenes but superior against S. aureus (P < 0.01). Mupirocin cream had a similar efficacy to fusidic acid cream against S. aureus but was significantly superior against S. pyogenes (P < 0.01). A hamster impetigo model infected with S. aureus was also used. Topical or oral treatment was administered at 24 and 30 h postinfection (also 36 h postinfection for oral therapy) and then three times daily for a further 2 days. On day 5, mupirocin cream was significantly more effective than mupirocin ointment in one study (P < 0.01) and of similar efficacy in the other two studies. Mupirocin cream was not significantly different from fusidic acid cream or neomycin-bacitracin cream, but it was significantly superior (P < 0.01) to oral erythromycin and cephalexin. Mupirocin cream was as effective as, or superior to, oral and other topical agents commonly used for skin infections.  (+info)

Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline. (6/84)

A 67 year old woman taking a monoamine oxidase inhibitor (MAOI) presented to the accident and emergency department with an anaphylactic reaction to flucloxacillin. This case highlights the uncertainty regarding the use of adrenaline (epinephrine) in the context of concurrent MAOI use. A summary of the evidence is presented to clarify this.  (+info)

Reversible sensorineural hearing loss after non-otological surgery under general anaesthetic. (7/84)

Acute sensorineural hearing loss can occur after both otolaryngological and non-otolaryngological procedures. The mechanism of such hearing loss remains unproved; but nitrous oxide has been implicated and where used, attendants should be aware of its potential damage to hearing. It is essential that patients with sudden hearing loss are identified as soon as possible as the recovery rate had been shown to be higher in those who presented early; and as our case demonstrates, complete recovery is possible. Anaesthetists, non-otolaryngological surgeons, and ward nurses must be aware of this early postoperative complication if appropriate treatment is to be instituted.  (+info)

Pyomyositis of the iliacus muscle in a child. (8/84)

Pyomyositis is rarely seen in temperate climates. Typically, it presents with the formation of an abscess requiring surgical drainage and it has been reported as a differential diagnosis for septic arthritis of the hip. We describe the occurrence of pyomyositis of the iliacus muscle in a ten-year-old girl which was diagnosed by MRI and blood culture. Formation of an abscess did not occur despite marked focal inflammation and swelling of the muscle. Conservative treatment with antibiotics alone led to complete clinical and radiological resolution of the infection. We could find no previous description of pyomyositis in a child in the British orthopaedic literature. Orthopaedic surgeons, particularly those with a paediatric interest, should be aware of this condition and its presentation, diagnosis and treatment.  (+info)

Flucloxacillin is not strictly a medical "definition," but rather it is an antibiotic medication used to treat infections caused by susceptible gram-positive bacteria, such as Staphylococcus aureus, including methicillin-sensitive strains. It is a semisynthetic penicillin derivative that is resistant to degradation by beta-lactamases produced by many bacteria, making it effective against some bacteria that are resistant to other penicillins.

Flucloxacillin works by inhibiting the synthesis of bacterial cell walls, leading to bacterial death. It is often used to treat skin and soft tissue infections, bone and joint infections, and endocarditis caused by susceptible organisms. Like other antibiotics, flucloxacillin should be used judiciously to prevent the development of antimicrobial resistance.

It's important to note that the use of any medication, including flucloxacillin, should be under the guidance and supervision of a healthcare professional, who can consider the individual patient's medical history, current medications, and other factors to determine the most appropriate treatment.

"Floxacillin". Drug Information Portal. U.S. National Library of Medicine. Portal: Medicine (Use dmy dates from June 2022, ... Flucloxacillin, also known as floxacillin, is an antibiotic used to treat skin infections, external ear infections, infections ...
Floxacillin / adverse effects * Floxacillin / pharmacokinetics * Humans * Inactivation, Metabolic / physiology * Mice * ...
Additive: Floxacillin, furosemide. Syringe: Doxapram. Y-site: Check with manufacturer. IV/IM Administration. May be ...
Floxacillin co-treated with alpha-galactosylceramide] results in increased expression of GPT protein. CTD. PMID:30993380. NCBI ...
Additive: Clindamycin, floxacillin, furosemide, gentamicin (incompatible in total parenteral nutrition [TPN]), metronidazole, ...
BRL-2039, BRL2039, floxacillin fludalanine 10810 3-fluoro-D-alanine, MK-0642, MK0642 ...
Floxacillin Susc Islt 3 LOINC_Long_Common_Name LOINC Long Common Name Floxacillin [Susceptibility] ...
I am a breastfeeding mother and i want to know if it is safe to use Oxiconazole? Does Oxiconazole has any short or long term side effects on infant?
2941.10.30 - Carfecillin, sodium; cloxacillin, sodium; dicloxacillin, sodium; flucloxacillin (Floxacillin); and oxacillin, ...
I am a breastfeeding mother and i want to know if it is safe to use Mectizan? Does Mectizan has any short or long term side effects on infant?
The LactMed® database contains information on drugs and other chemicals to which breastfeeding mothers may be exposed. It includes information on the levels of such substances in breast milk and infant blood, and the possible adverse effects in the nursing infant. Suggested therapeutic alternatives to those drugs are provided, where appropriate. All data are derived from the scientific literature and fully referenced. A peer review panel reviews the data to assure scientific validity and currency.
Flucloxacillin (Floxacillin) Sodium Compacted. phenobarbital sodium. AZITHROMYCIN. Flucloxacillin (Floxacillin) Sodium Powder. ...
Flucloxacilin, also known as floxacillin. When one hookworm host took this drug with probenecid (which is sometimes used to ...
Additive: Aminophylline, amobarbital, chlorothiazide, floxacillin, fluorouracil, heparin, meperidine, midazolam(?), ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
Floxacillin D2.886.675.966.500.750.625.150.250 D2.886.108.750.625.150.250. D4.75.80.875.99.221.750.625.150.250. Flufenamic Acid ...
... floxacillin sodium, metronidazole (with or without sodium bicarbonate), ranitidine HCl, and vera-pamil HCl. Several other drugs ...
This is possibly the most important incompatibility associated with the use of Floxacillin. ...

No FAQ available that match "floxacillin"

No images available that match "floxacillin"